Chemomab Therapeutics Ltd DRC (CMMB)

Currency in USD
0.9500
-0.0199(-2.05%)
Closed·
After Hours
0.9400-0.0100(-1.05%)
·
CMMB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CMMB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.92000.9800
52 wk Range
0.87202.5500
Key Statistics
Prev. Close
0.95
Open
0.9695
Day's Range
0.92-0.98
52 wk Range
0.872-2.55
Volume
138.37K
Average Volume (3m)
152.12K
1-Year Change
1.79%
Book Value / Share
0.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CMMB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.5000
Upside
+794.74%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Chemomab Therapeutics Ltd DRC Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Compare CMMB to Peers and Sector

Metrics to compare
CMMB
Peers
Sector
Relationship
P/E Ratio
−1.4x−2.9x−0.5x
PEG Ratio
−0.02−0.050.00
Price/Book
1.8x2.5x2.6x
Price / LTM Sales
-11.1x3.3x
Upside (Analyst Target)
-580.3%42.9%
Fair Value Upside
Unlock8.9%6.2%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 8.5000
(+794.74% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-0.01 / -0.01
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CMMB Income Statement

People Also Watch

17.94
SRPT
-1.59%
1.9700
DARE
+2.60%
0.6798
GOVX
+0.12%
0.341
VYNE
-4.48%
10.0300
ARTL
+20.12%

FAQ

What Stock Exchange Does Chemomab Therapeutics DRC Trade On?

Chemomab Therapeutics DRC is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Chemomab Therapeutics DRC?

The stock symbol for Chemomab Therapeutics DRC is "CMMB."

What Is the Chemomab Therapeutics DRC Market Cap?

As of today, Chemomab Therapeutics DRC market cap is 18.21M.

What Is Chemomab Therapeutics DRC's Earnings Per Share (TTM)?

The Chemomab Therapeutics DRC EPS (TTM) is -0.67.

When Is the Next Chemomab Therapeutics DRC Earnings Date?

Chemomab Therapeutics DRC will release its next earnings report on 06 Nov 2025.

From a Technical Analysis Perspective, Is CMMB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Chemomab Therapeutics DRC Stock Split?

Chemomab Therapeutics DRC has split 1 times.

How Many Employees Does Chemomab Therapeutics DRC Have?

Chemomab Therapeutics DRC has 3 employees.

What is the current trading status of Chemomab Therapeutics DRC (CMMB)?

As of 12 Aug 2025, Chemomab Therapeutics DRC (CMMB) is trading at a price of 0.95, with a previous close of 0.95. The stock has fluctuated within a day range of 0.92 to 0.98, while its 52-week range spans from 0.87 to 2.55.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.